Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy

AIDS Research and Human Retroviruses

Volumn 23, Issue 1, 2007, Pages 54-61

  Chêne, Geneviève ^a,b   Amellal, Bahia ^c   Pédrono, Gaëlle ^a   Gourlain, Karine ^c   Rancinan, Corinne ^a   Journot, Valérie ^a   Cotte, Laurent ^d   Palmer, Pierre ^e   De Castro, Nathalie ^f   Calvez, Vincent ^c   Molina, Jean Michel ^e   Aboulker, J P ^ae   Decazes, J M ^e   Dormont, J ^ae   Dumon, B ^ae   Ferchal, F ^ae   Madelaine, I ^ae   Metro, A ^ae   Meyohas, M C ^f,ae   Modai J ^e   Pellegrin, I ^ae   Raffi, François ^w,ae   Salamon, R ^ae   Sombardier, M N ^e   Yeni P ^ae   Cabotin, P ^e   Garrait, V ^e   Goguel, J ^e   Kouchner, G ^e   Lesprit, P ^e   Ponscarme, D ^e   Martinie, M ^e   Morel, P ^e   Picard, V ^e   Spindler, E ^e   Timsit, J ^e   Roue R ^g   Debord, T ^g   Teyssou, R ^h   Nicand, E ^h   Champetier De Ribes, D ⁱ   Forces, G ⁱ   Devidas, A ^j   Chevozon, P ^j   Malkin, J E ^k   Semaille, C ^k   Cessut, G ^k   Haliona, B ^k   Rochemaure, J ^l   Compagnucci, A ^l   Marsal, L ^l   Krulik, M ^f   Duvivier, C ^c,f   Adda, N ^f   Frottier, J ^f   Gentil, C ^f   Bollens, D ^f   Gaujour, B ^f   Deifraissy, J F ^m   Goujard, C ^m   Peretti, D ^m   Rannou, M T ^m   Caulin, C ⁿ   Segrestaa, J M ⁿ   Bergmann, J F ⁿ   Bonfanti, M ⁿ   Salord, J M ⁿ   Vincent, V ⁿ   Badsi, E ⁿ   Cervoni, J ⁿ   Cocheton, J J ^o   Delzant, G ^o   Leconte, I ^o   Lascoux, C ^o   Zurita, C ^o   Vasseur, E ^o   Bentata, M ^p   Pathe, J P ^p   Mosnier Mantel, A ^p   Attia, M ^p   Guillevin, L ^p   Jarrousse, B ^p   Cohen, P ^p   Lortholary, O ^p   Honore P ^p   Galanaud, P ^q   Boue F ^q   Colson, P ^q   Herson, S ^c   Bonmarchand, M ^c   Brancon, C ^c   Coutelier, A ^c   Karmochkine, M ^c   Larrue, F ^c   Vuitton, D ^r   Gil, H ^r   Bourezane, Y ^r   Dupont, J L ^s   Hoen, B ^s   Derancourt, C ^s   Drobacheff, C ^s   Salard, D ^s   Laurent, R ^s   Estavoyer, J M ^s   Remy G ^t   Beguinot, I ^t   Rouger, C ^t   Lepeu, G ^u   De La Blanchardiere A ^u   Brun, G ^u   Touchais, A M ^u   Boulat, O ^u   Zerazhi, H ^u   Beylot, J ^v   Morlat, P ^v   Lacoste, D ^v   Bernard, N ^v   Bonarek, M ^v   Bonnet, F ^v   Nouts, C ^v   Trepo, C ^d   Cotte, L ^d   Schlienger, I ^d   Rougier, P ^d   Cane, C ^d   Benmakhlouf, N ^d   Bailly, F ^d   Billaud, E ^w   Allavena, C ^w   Francois C ^w   Leaute, S ^w   Milpied, B ^w   Charonnat, M F ^w   Sicot, M ^w   Cartier, F ^x   Michelet, C ^x   Chapplain, J M ^x   Favre, C ^x   Andrieux, F ^x   Arvieux, C ^x   Lombart, M L ^x   Stagnetto, C ^x   Souala, F ^x   Lang, J M ^y   Nicolle, M ^y   Rey, D ^y   Bernard Henry, C ^y   Krantz, V ^y   Hess Kempf, G ^y   Massip, P ^z   Bicart See, A ^z   Obadia, M ^z   Cuzin, L ^z   Penecy, J ^z   Marchou, B ^z   Balsarin, F ^z   Portier, H ^aa   Chavanet, P ^aa   Buisson, M ^aa   Piroth, L ^aa   Waldner, A ^aa   Grappin, M ^aa   Greusard, M C ^aa   Leclercq, P ^ab   Bouchard, D ^ab   Ruiz, D ^ab   Gailland, M C ^ab   Canton, P ^ac   Burty, C ^ac   Brel, F ^ac   May, T ^ac   Doco Lecompte, T ^ac   Leduc, D ^ad   more..

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g SERVICE D ENDOCRINOLOGIE   (France)

^h University of Paris Descartes   (France)

ⁱ Hôpital N D du Perpétuel Secours   (France)

^j CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^k INSTITUT ALFRED FOURNIER   (France)

^l HÔTEL DIEU   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ HÔPITAL LARIBOISIÈRE   (France)

^o HÔPITAL TENON   (France)

^p AVICENNE HOSPITAL   (France)

^q HÔPITAL ANTOINE BÉCLÈRE   (France)

^r UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^s HÔPITAL SAINT JACQUES   (France)

^t SERVICE DE DERMATOLOGIE   (France)

^u CENTRE HOSPITALIER D AVIGNON   (France)

^v HÔPITAL SAINT ANDRÉ   (France)

^w HÔTEL DIEU   (France)

^x PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^y HÔPITAL CIVIL   (France)

^z CHU PURPAN   (France)

^aa HÔPITAL DU BOCAGE   (France)

^ab HÔPITAL MICHALLON   (France)

^ac CHU NANCY BRABOIS   (France)

^ad Hôpital Intercommunal Annemasse Bonneville

^ae Hôpital du Bocage ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CRYOPRESERVATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION;

EID: 33846844983     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0039     Document Type: Article

References (35)

1. Brinkrnan K, Smeitink JA, Romijn JA, and Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-trasncriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy related lipodystrophy. Lancet 1999;354:1112-1115.
2. Carr A, Miller J, Law M, and Cooper DA: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
3. Mallal SA, John M, Moore CB, James IR, and McKinnon EJ: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316.
4. Martin A, Smith D, Carr A, Ringland C, Amin J, et al.: Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX extension study. AIDS 2004;18:1029-1036.
5. Joly V, Flandre P, Meiffredy V, et al.: Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS 2002;16:2447-2454.
6. Shikuma C, Hu M, Milne C, Yost F, Waslien C, and Shimizu S: Mitochondrial DNA decrease in subcutaneous adipose tissue on HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-1809.
7. Nolan D, Hammond E, Martin A, et al.: Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338.
8. Cherry C, Gahan M, McArthur J, Lewin S, Hoy J, and Wesselingh S: Exposure to dideoxynucleosides is reflected in a lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002;30:271-277.
9. Miro O, Lopez S, Pedrol E, et al.: Mitochondrial DNA depletion and respiratory chain enzyme deficiencies present in peripheral blood mononuclear cells of HIV-infected patients HAART-related lipodystrophy. Antiviral Ther 2003;8:333-338.
10. Gahan M, Miller F, and Lewin S: Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. J Clin Virol 2001;22:241-247.
11. Reiss P, Casula M, de Ronde A, Weverling G, Goudsmit J, and Lange J: Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine + didanosine or zidovudine + zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HW Med 2004;5:11-14.
12. Molina J, Chêne G, Ferchal F, et al.: The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis 1999;180:351-358.
13. Chêne G, Angelini E, Cotte L, et al.: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:649-657.
14. Bieche, Olivi M, Champeme M, Vidaud D, Lidereau R, and Vidaud M: Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-666.
15. Gourlain K, Amellal B, Ait Arkoub Z, Dupin N, Katlama C, and Calvez V: Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Med 2003;4:287-292.
16. Côté H, Brumme Z, Craib K, Alexander C, Wynhoven B, and Ting L: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
17. Walker U, Bauerle J, Laguno M, et al.: Depletion of mitochondrial DNA in liver under antiretroviral therapy: Didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-317.
18. Benbrik E, Chariot P, Bonavaud S, et al.: Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149:19-25.
19. Côté H, Yip B, Asselin J, et al.: Mitochondrial-nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected antiretroviral drug regimens. J Infect Dis 2003;187:1972-1976.
20. Carr A, Workman C, Smith D, et al.: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. A randomized trial. JAMA 2002;288:207-215.
21. Simpson D and Tagliati M: Nucleoside analogue-associated peripheral neuropathy in HIV-infection. J Acquir Immune Defic Syndr 1995;9:153-161.
22. Lopez S, Miro O, Martinez E, et al.: Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antiviral Ther 2004;9:47-55.
23. Casula M, Weverling GJ, Wit FW, et al.: Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005;192:1794-1800.
24. Cossarizza A, Riva A, Pinti M, et al.: Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antiviral Ther 2003;8:315-321.
25. Casula M, Bosboom-Dobbelaer I, Smolders K, et al.: Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005;191:1468-1471.
26. de Mendoza C, de Ronde A, Smolders K, et al.: Changes in mitochoondiral DNA copy number in blood cells from HIV-infected pateints undergoing antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:271-273.
27. Miro O, Lopez S, Martinez E, et al.: Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004;39:710-716.
28. Hoy J, Gahan M, Carr A, et al.: Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004;190:688-692.
29. McComsey GA, Paulsen DM, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23.
30. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, and Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005;6:197-202.
31. Mussini C, Pinti M, Bugarini R, et al.: Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: A prospective study. AIDS 2005;19:1627-1633.
32. Saint-Marc T, Partisani M, Poizot-Martin I, et al.: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-1667.
33. HIV Lipodystrophy Case Definition Study Group: An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003;361:726-735.
34. Van der Valk M, Casula M, Weverling G, et al.: Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Ther 2004;9:385-393.
35. Rabing Christensen R, Stegger M, Jensen-Fangel S, Laursen A, and Ostergaard L: Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: A randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004;39:1371-1379.